scholarly journals Human Insulin (Entuzity KwikPen)

2021 ◽  
Vol 1 (10) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Diabetes Mellitus ◽  
Cost Effectiveness ◽  
Glycemic Control ◽  
Human Insulin ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Insulin Injection ◽  
Subcutaneous Insulin ◽  
Adults And Children ◽  
Clinician Perspectives

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses human biosynthetic insulin (Entuzity KwikPen), 500 units/mL subcutaneous insulin injection, human biosynthetic, solution for injection Indication: Entuzity is indicated to improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day

scholarly journals Semaglutide (Rybelsus)

2021 ◽  
Vol 1 (9) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Cost Effectiveness ◽  
Glycemic Control ◽  
Oral Administration ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Medicinal Products ◽  
Diet And Exercise ◽  
Clinician Perspectives ◽  
Treatment Of Diabetes

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses semaglutide (Rybelsus), 3 mg, 7 mg, and 14 mg tablets, for oral administration Indication: Semaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2DM: as monotherapy when metformin is considered inappropriate due to intolerance or contraindications; in combination with other medicinal products for the treatment of diabetes.

scholarly journals Degradation of Insulin Amyloid by Antibiotic Minocycline and Formation of Toxic Intermediates

2021 ◽  
Author(s):  
Wakako Mori ◽  
Keisuke Yuzu ◽  
Nadine Lobsiger ◽  
Hideo Nishioka ◽  
Hisako Sato ◽  
...  
Keyword(s):  
Glycemic Control ◽  
Human Insulin ◽  
Insulin Injection ◽  
Subcutaneous Insulin ◽  
Insulin Absorption ◽  
Insulin Analogs ◽  
Diabetes Therapy ◽  
Toxic Species ◽  
Patients With Diabetes ◽  
Initial Appearance

Abstract Insulin balls, localized insulin amyloids formed at subcutaneous insulin-injection sites in patients with diabetes, cause poor glycemic control owing to impairments in insulin absorption. Our previous study has shown that some insulin balls are cytotoxic, but others are not, implying amyloid polymorphism. Interestingly, the patient with toxic insulin balls had been treated with antibiotic minocycline, suggesting a possible relationship between toxicity of insulin balls and minocycline. However, the direct effect of minocycline on the structure and cytotoxicity of the insulin amyloid is still unclear. Herein, we demonstrated that that minocycline at physiological concentrations induced degradation of insulin amyloids formed from human insulin and insulin drug preparations used for diabetes patients. Interestingly, the process involved the initial appearance of the toxic species, which subsequently changed into less-toxic species. It is also shown that the structure of the toxic species was similar to that of sonicated fragments of human insulin amyloids. Our study shed new light on the clarification of the revelation of insulin balls and the development of the insulin analogs for diabetes therapy.

scholarly journals Nivolumab (Opdivo) in combination with Ipilimumab (Yervoy)

2021 ◽  
Vol 1 (9) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Cost Effectiveness ◽  
Systemic Therapy ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Adult Patients ◽  
Clinician Perspectives ◽  
Prior Systemic Therapy

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses nivolumab (Opdivo) 10 mg/mL for injection; administered by IV infusion and ipilimumab (Yervoy) 5 mg/mL for injection; administered by IV infusion Indication: Nivolumab (Opdivo) in combination with ipilimumab (Yervoy) is indicated for the treatment of adult patients with unresectable MPM who have not received prior systemic therapy for MPM

scholarly journals Luspatercept (Reblozyl)

2021 ◽  
Vol 1 (8) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Cost Effectiveness ◽  
Blood Cell ◽  
Red Blood Cell ◽  
Subcutaneous Injection ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Adult Patients ◽  
Red Blood Cell Transfusion ◽  
Beta Thalassemia ◽  
Clinician Perspectives

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses luspatercept (Reblozyl), 25 mg/vial, 75 mg/vial, powder for solution for subcutaneous injection. Indication: For the treatment of adult patients with red blood cell transfusion-dependent anemia associated with beta-thalassemia.

scholarly journals Risperidone for Extended-Release Injectable Suspension (Perseris)

2021 ◽  
Vol 1 (11) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Cost Effectiveness ◽  
Subcutaneous Injection ◽  
Extended Release ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Clinician Perspectives

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses risperidone for extended-release injectable suspension (Perseris), powder for suspension, 90 mg or 120 mg subcutaneous injection. Indication: Treatment of schizophrenia in adults.

Venetoclax (Venclexta)

2021 ◽  
Vol 1 (10) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Cost Effectiveness ◽  
Induction Chemotherapy ◽  
Low Dose ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Newly Diagnosed ◽  
Clinician Perspectives ◽  
Low Dose Cytarabine

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses venetoclax (Venclexta), 10 mg, 50 mg, and 100 mg oral tablets. Indication: In combination with azacitidine or low-dose cytarabine for the treatment of patients with newly diagnosed AML who are 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.

scholarly journals Pembrolizumab (Keytruda)

2021 ◽  
Vol 1 (9) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Colorectal Cancer ◽  
Cost Effectiveness ◽  
Microsatellite Instability ◽  
Mismatch Repair ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Line Treatment ◽  
First Line ◽  
Clinician Perspectives ◽  
First Line Treatment

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses pembrolizumab (Keytruda) 200 mg administered intravenously Indication: As monotherapy, for the first-line treatment of adults with metastatic microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) colorectal cancer

scholarly journals Pembrolizumab (Keytruda)

2021 ◽  
Vol 1 (12) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Cost Effectiveness ◽  
Pediatric Patients ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Salvage Chemotherapy ◽  
Clinician Perspectives ◽  
Multi Agent

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses pembrolizumab (Keytruda) 200 mg in adults or 2 mg/kg in pediatrics administered intravenously every 3 weeks. Indication: Treatment of adult and pediatric patients with refractory or relapsed cHL, as monotherapy, who have failed ASCT, or who are not candidates for multi-agent salvage chemotherapy and ASCT.

scholarly journals Upadacitinib (Rinvoq)

2021 ◽  
Vol 1 (10) ◽  
Author(s):  
Reimbursement Reviews
Keyword(s):  
Psoriatic Arthritis ◽  
Cost Effectiveness ◽  
Extended Release ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Inadequate Response ◽  
Clinician Perspectives

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses upadacitinib (Rinvoq) 15-mg extended-release oral tablets Indication: For the treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other DMARDs; Rinvoq (upadacitinib) may be used as monotherapy or in combination with methotrexate

scholarly journals Daunorubicin and Cytarabine Liposome (Vyxeos)

2021 ◽  
Vol 1 (10) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Acute Myeloid Leukemia ◽  
Cost Effectiveness ◽  
Myeloid Leukemia ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Newly Diagnosed ◽  
Clinician Perspectives ◽  
Acute Myeloid

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses dunorubicin and cytarabine liposome for injection, 44 mg daunorubicin and 100 mg cytarabine per vial, IV infusion Indication: Treatment of adults with newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes

Sign in / Sign up

Export Citation Format

Share Document